Physician profile
Mark E Ponder
NPI 1023047529
$7,463.38
in general payments reported to CMS, 2019-2025
28 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $1,475 · 2021: $1,452 · 2022: $1,014 · 2023: $989 · 2024: $922 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.50 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,100.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,107.42 | 2021-2025 | |
| Lilly USA, LLC | $1,041.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $403.36 | 2019-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $321.20 | 2019-2023 | Belsomra, Verquvo |
| Janssen Pharmaceuticals, INC | $286.90 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $283.14 | 2022-2025 | |
| Pfizer INC. | $219.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.30 | 2019-2022 | |
| Axsome Therapeutics, INC. | $213.02 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.53 | 2020-2024 | Jardiance |
| Amarin Pharma, INC. | $136.68 | 2019-2021 | |
| Allergan, INC. | $124.15 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $109.63 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.10 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $103.26 | 2022-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $95.75 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $72.94 | 2020-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $63.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.50 | 2019-2023 | |
| Amgen INC. | $55.28 | 2019-2025 | Evenity, Otezla, Repatha |
| Genentech USA, INC. | $23.56 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.56 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.80 | 2024 | Evkeeza |
| Abbott Laboratories | $17.85 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.95 | 2025 | Caplyta |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.18 | 2021 | |
| Sanofi Pasteur INC. | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ponder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.